KRAS and neoplasm: Therefore, advanced combination treatments including, e.g. CD40 agonists, TGFβ blockade, or therapeutics targeting KRAS signaling, the myeloid compartment, or tumor stroma (63, 64) may improve efficacy of virotherapy plus checkpoint blockade in PDAC.